跳至主要内容
临床试验/NCT01055353
NCT01055353已完成不适用

Evaluation of Target Organs Damage in Hypertensive Patients Followed in General Practice With no Known Cardiovascular (CV) or Renal Disease, Stratified According to Blood Pressure Control

AstraZeneca1 个研究点 分布在 1 个国家目标入组 1,857 人开始时间: 2010年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
1,857
试验地点
1
主要终点
To evaluate the frequency of evaluation of preclinical target organs damage in hypertensive patients with no known cardiovascular or renal disease, by taking blood pressure (controlled or uncontrolled HT*) into account

研究概览

简要总结

Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosis of essential hypertension (treated or untreated); HT not discovered on the day of the consultation; no documented clinical cardiovascular or renal disease.

排除标准

  • 未提供

结局指标

主要结局

To evaluate the frequency of evaluation of preclinical target organs damage in hypertensive patients with no known cardiovascular or renal disease, by taking blood pressure (controlled or uncontrolled HT*) into account

时间窗: once / 1 Year

次要结局

  • To describe the patient profile (socio-demographic, risk factors, comorbidities, global CV risk level estimated by the doctor and calculated retrospectively [according to ESH 2007]) associated with screening for target organs damage
  • To describe the modalities of patient follow-up and management
  • To compare the frequency of evaluation of target organs damage as a function of the modalities of management of CV risk factors at the time of the consultation.

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验